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Abstract Squamous cell carcinoma antigen (SCCA) is
expressed in normal squamous cell epithelia and in
squamous cell carcinomas (SCC). Two nearly identical
genes encode the inhibitory serpins SCCA1 (SERPINB3)
and SCCA2 (SERPINB4). Serum levels of SCCA are
elevated in patients with benign skin diseases and in
patients with SCC. SCCA, used for the monitoring of
SCC patients, presents no satisfactory diagnostic specificity.
As we have shown previously, the reverse transcription
polymerase chain reaction (RT-PCR)-based SCCA messen-
ger RNA (mRNA) testing aimed at detecting disseminated
cancer cells may be hampered by the false-positive results
due to SCCA expression in activated peripheral blood
mononuclear cells (PBMC). The aim of this study was to
assess the expression of SCCA at mRNA and protein levels
in cultured normal PBMC, compared to that in vulvar SCC
(VSCC) samples. High SCCA concentrations were found in
vulvar tumours and in metastatic lymph nodes, while
negative inguinal lymph nodes from the same patients
often presented significantly less SCCA. In normal activat-
ed PBMC, the level of SCCA protein was the lowest. At the
mRNA level SCCA was detectable in normal PBMC even
in cultures with no mitogen stimulation, but only by the
nested RT-PCR, contrary to VSCC samples found to be
SCCA positive already in one-step PCR. Both SCCA1 and
SCCA2 transcripts were present in cultured PBMC;
SCCA1 was expressed at a higher level than SCCA2. In
conclusion, both SCCA forms are detectable in normal
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DOI 10.1007/s13277-010-0069-xPBMC cultured in vitro. SCCA expression level in normal
PBMC is much lower than in the squamous epithelium-
derived cells. In VSCC, in addition to tumour itself,
metastatic lymph nodes seem also to be a potential source
of serum SCCA.
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Introduction
Squamous cell carcinoma antigen (SCCA), first discovered
in the squamous cell carcinoma of the cervix [1], is
expressed in different squamous cell carcinomas (SCC)
and in normal squamous cell epithelia. SCCA belongs to
the family of inhibitory serine protease inhibitors (serpins),
involved in apoptosis, cell migration and invasiveness [2].
Elevated levels of serum SCCA proteins are common in
patients with benign, inflammatory skin diseases, such as
psoriasis and atopic dermatitis, as well as in patients with
squamous cell carcinomas, especially of the cervix, head
and neck, lung, oesophagus and vulva, where SCCA
concentrations may correlate with clinical stage, histolog-
ical grade and tumour burden [1, 3–7]. Serum SCCA has an
independent prognostic value in patients with cervical
carcinoma and with head and neck malignancies [6, 8]
and is used for the diagnosis and monitoring of patients
with SCC [9]. There are two SCCA proteins, encoded by
two, nearly identical genes, SCCA1 (SERPINB3) and
SCCA2 (SERPINB4). SCCA1 and SCCA2 proteins,
although they present 92% amino acid sequence homology
and target different proteases. The neutral SCCA1 inhibits
papaine-like lysosomal cysteine proteases, cathepsine S, L
and K, and the acidic SCCA2 inhibits the serine proteases,
cathepsine G and mast cell chymase [10, 11].
Both SCCA proteins are colocalised in normal and
malignant squamous epithelial cells, but the dominating
serum form in patients with SCC is SCCA2 [12–14].
Elevated SCCA2/SCCA1 messenger RNA (mRNA) ratio in
primary SCC of the head and neck and of cervix was found
to be an independent predictor of tumour recurrence
[15, 16]. SCCA is also regarded as a molecular tumour
marker for disseminated SCC cell detection [17]. However,
as we have previously shown while studying the question of
false-positive reverse transcription polymerase chain reaction
(RT-PCR) results of disseminated cancer cell detection [18],
there is an expression of a number of the so-called tumour-
specific molecular markers, including SCCA, in activated
peripheral blood mononuclear cells (PBMC).
Here, we aimed to study the total SCCA as well as
SCCA1 and SCCA2 expression at both the mRNA and
protein levels, in normal unstimulated and PHA-stimulated
PBMC, and to compare the obtained total SCCA protein
expression to that in vulvar squamous cell carcinoma
(VSCC), one of many types of SCCs.
Material and methods
PBMC and cell lines
PBMC of six healthy donors were obtained by standard
Ficoll-Paque (Pharmacia) gradient centrifugation; samples
of uncultured cells were taken, and the remaining cells were
cultured in a standard medium supplemented with 10%
fetal calf serum (FCS) and gentamycin, for 1 day without
mitogen, and in paralell, for 1–6 days in the presence of
PHA (1 μg/ml). Cultures were centrifuged, supernatants
were collected and frozen, cells were washed twice in PBS
and the cell pellet was kept frozen at −70°C until RNA was
isolated.
Squamous epithelial cell lines, the epidermoid vulvar
carcinoma cell line, A431 (Deutsche Sammlung von
Zellkulturen und Mikroorganismen, Braunschweig,
Germany), the human cervical carcinoma cell line, SKG-
IIIa (RINKEN BRC, National Bio-Resource Project of the
MEXT, Japan), the supraglottic larynx carcinoma cell line,
UT-SCC-8 (The University of Turku, Finland), and the
human keratinocyte cell line, HaCat [19], as well as the
cervix adenocarcinoma cell line, HeLa (Warsaw Medical
University, Warsaw Poland), were cultured at 37°C, 5%
CO2 in the standard media supplemented with 10% FCS
and gentamycin.
Post-surgical samples from vulvar carcinoma patients
We studied the samples obtained from surgical specimens
of 41 patients treated in the Maria Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology for
VSCC (pT1-2, N0-2, M0). All patients gave their informed
consent. Samples including 39 tumours, 15 regional lymph
nodes and 36 uninvolved adjacent tissues were snap-frozen
and stored at −70°C until they were pulverised on liquid
nitrogen, using a Microdismembrator II (B Braun Biotech
International, Melsungen, Germany). The uninvolved
tissues comprised cross-sections of skin next to the surgical
margin. Histologically, they were composed of dermis and
the epidermal layer.
RNA isolation and RT-PCR
Total RNA was isolated from PBMC at each time point (0,
before culture; unstimulated 1-day cultures; and PHA-
stimulated 1–6-day cultures ) and from pulverised post-
surgical samples from VSCC patients with the use of
560 Tumor Biol. (2010) 31:559–567Quiagen RNeasy kits. The quantity and quality of the RNA
that was obtained were examined by spectrophotometry
(Nanodrop, Thermoscientific) and by denaturing gel elec-
trophoresis with ethidium bromide. Two micrograms of the
total RNA was reverse transcribed with random hexamer
primers, in the final volume of 20 μl, using SuperScript
reverse transcriptase (Invitrogen), according to the manu-
facturer’s instructions. The quality of complementary DNA
preparations was controlled by the PCR of DNA polymerase
β, as described previously [18]. Total SCCA, SCCA1 and
SSCA2 expression was analysed in PBMC by the nested
RT-PCR with specific primers. Tissue samples obtained from
VSCC patients were examined for total SCCA expression by
one-step RT-PCR.
Measurements of SCCA protein expression
Total cell protein was extracted from unstimulated and
stimulated PBMC of four normal donors and from
pulverised post-surgical samples of seven patients with
vulvar cancer, according to the procedure described
elsewhere [13].
Total SCCA expression in the protein extracts of PBMC
and vulvar tumours, the concentrations of SCCA (total) in
culture media and 22 patients’ sera were measured using the
Architect SCCA kit of Abbott, and SCCA in protein
extracts were expressed in nanogram per milligram of cell
protein (CP), while in the sera and culture media in
nanogram per millilitre.
Immunocytochemical staining was performed using
primary anti-SCCA1, anti-SCCA2 MAb (Santa Cruz,
8H11 and 10C12, respectively) and secondary anti-mouse
IgG rabbit antibody Alexa 633 conjugated (Invitrogen).
Nuclei were counterstained with chromomycin A3 (Sigma),
and the results were imaged with confocal microscope
(Axiovert 100 M, Zeiss) and LSM 510 META application.
Immunohistochemical staining was performed with anti-
SCCA1 (8H11), anti-SCCA2 (10C12) and anti-total SCCA
(B-9) MAbs (Santa Cruz). Nuclei were counterstained with
haematoxylin and eosin, and the results were imaged under
a light microscope.
Results
The specific primers for total SCCA, SCCA1 and SCCA2
amplified the correct sequences, as confirmed by sequenc-
ing. As shown by the nested RT-PCR, total SCCA was
expressed in mitogen-stimulated PBMC, where it persisted
for all 6 days of culture, as well as in unstimulated PBMC
following 1-day culture without mitogen (Fig. 1 and
Table 1). SCCA was undetectable in the freshly isolated
PBMC.
The SCCA1 and SCCA2 genes usually co-expressed in
PBMC, and this was also observed in cultures with no
mitogen stimulation. In PBMC from donor I, the level of
SCCA1 expression was constant up to 3 days of culture, but
in the subsequent 3 days, PBMC presented no SCCA1
expression, in contrast to SCCA2, which was detectable
throughout the whole culture period (Fig. 2 and Table 1).
The level of SCCA2 expression assessed semiquantitatively
in 1-day cultures was found to be lower than that of
SCCA1, in both stimulated and unstimulated PBMC of
donor I (Fig. 3). The total SCCA was found to be
consequently expressed in PBMC of all donors throughout
the culture, while the SCCA1 and SCCA2 gene expression,
although found to be expressed in all donors, was identified
in different time points in different donors (Table 1).
The SCCA mRNA expression in post-surgical samples
from patients with VSCC was also examined. Already in
one-step PCR, all 39 tumour samples were SCCA positive,
while the squamous cell vulvar carcinoma cell line A431
was SCCA negative (A431 was positive in two-step PCR).
The SCCA transcripts were also detected in 31 out of 36
uninvolved adjacent tissues (86%).
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Fig. 1 Expression of total SCCA mRNA in PBMC from donor I
(0—before culture, 1—unstimulated 1-day culture and PHA stimulated
1–6 day cultures)
Tumor Biol. (2010) 31:559–567 561The SCCA concentration in the protein extract of
activated PBMC was found to reach 2.7 ng/mg of CP
(mean, 2.15 ng/mg; Table 2). In the post-surgical samples
from VSCC patients, SCCA concentrations were two to
four orders of magnitude higher than those in cultured
PBMC. The SCCA protein concentrations were usually
higher in the tumour than in the uninvolved adjacent tissue
(Table 2). Metastatic inguinal lymph nodes expressed
higher levels of SCCA protein than uninvolved inguinal
lymph nodes derived from the same patients. Interestingly,
in patients 12 and 30, the lymph nodes that had been
classified histpathologically as uninvolved (Table 2) pre-
sented relatively high SCCA levels. This might suggest that
these lymph nodes did contain micrometastases.
Immunocytochemical analysis under confocal micro-
scope has shown traces of SCCA 1 and 2 proteins in
cultured PBMC (Fig. 4). As shown in donor III, the SCCA1
and 2 expression at the protein level was detected in PBMC
later after stimulation than at the mRNA level (Table 3).
The immunohistochemical analysis of tumour and
inguinal lymph node from a patient with VSCC confirmed
the evidently stronger SCCA staining in the metastatic
lymph node than in the SCC sample (Fig. 5) and showed
that not only cancer cells express SCCA protein (Table 4).
SCCA secretion was examined in cell cultures. SCCA
was undetectable in the spent media from PBMC cultures,
as well as from HaCat keratinocyte cell line (<0.3 ng/ml),
while it was secreted in relatively high amounts by the
squamous cervical cancer cell line, SKG-IIIa (8 ng/ml),
known for high SCCA expression level.
The median SCCA level in the sera of 22 patients with
early VSCC was 1.35 ng/ml (7.4–0.6). Only four (18%) of
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Fig. 3 Semiquantitative assessment of SCCA1/SCCA2 expression
ratio in PBMC
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Fig. 2 SCCA1 and SCCA2 mRNA expression kinetics in stimulated
PBMC from donor I
Table 1 Total SCCA, SCCA1 and SCCA2 expression, assessed by the nested RT-PCR
Total SCCA SCCA1 SCCA2
Donor I II II II III III IV V VI I II II III IV V VI I II II III III IV V VI
Normal
PBMC
Days of
culture
0 −−−n.d. −−n.d. − n.d. −−−− n.d. − − − −−− − n.d. −−
1 d + + + n.d. + + n.d. n.d. n.d. + −−+ n.d. n.d. n.d. + + − + − n.d. n.d. n.d.
1 d/PHA + + + n.d. + + n.d. + + + −−− n.d. + + + −−− + n.d. + +
2 d/PHA + + + n.d. + + n.d. n.d. n.d. + + −− n.d. n.d. n.d. +/−−−− − n.d. n.d. n.d.
3 d/PHA + + + n.d. + + n.d. n.d. n.d. + − + − n.d. n.d. n.d. +/−−−− − n.d. n.d. n.d.
4 d/PHA + + + n.d. + + n.d. n.d. n.d. −−−− n.d. n.d. n.d. +/−−−− − n.d. n.d. n.d.
5 d/PHA + + − + − + n.d. n.d. n.d. −−−− n.d. n.d. n.d. +/−−−− − n.d. n.d. n.d.
6 d/PHA + + + n.d. + − + n.d. n.d. −−−− + n.d. n.d. + − − −−− n.d. n.d.
In donors II and III repeated assessments were performed
(+) present, (−) absent, (+/−) trace expression, n.d. not determined
562 Tumor Biol. (2010) 31:559–567those patients had elevated SCCA levels, and three had
SCCA at the cut-off level (2 ng/ml).
Discussion
We were the first to show the SCCA expression to be
inducible in normal PBMC [18]. Here, we studied the total
SCCA expression along with the expression of its acidic
and neutral forms in more detail. We confirmed our earlier
results [18] and those of Catatelpe [12], who studied
different normal tissues, that SCCA mRNA is not expressed
in uncultured normal PBMC. However, as we showed here,
normal, activated PBMCs express SCCA1 and SCCA2 at
both the mRNA and protein level. The two SCCA forms are
often identified in different time points following stimula-
tion, both in protein and mRNA studies. Interestingly, also
unstimulated PBMCs following culture in the presence of
FCS were found to express SCCA1 and SCCA2 trancripts.
In addition, both in unstimulated (cultured for 1 day without
mitogen) and in stimulated normal PBMC, the SCCA1
expression measured at the mRNA level was higher than the
SCCA2 expression. Our semiquantitative assessment of
the relative SCCA1 and SCCA2 expression revealed that
Table 2 SCCA concentrations (Abbott IMX SCCA assay) in the protein extracts of normal unstimulated (day 0) and stimulated (day 3) peripheral
blood mononuclear cells (PBMC) and of tissue samples as well as in the sera from patients with VSCC
Donor number Patient number
Healthy donor PBMC I II III IV
Unstimulated 0 0 0 0
Stimulated 2.7 2.7 1.4 1.8
Samples of VSCC 12 13 15 30 34 38 53
Tumour 850 4890 19000 1850 6000 481 1600
Adjacent uninvolved tissue 2920 290 2000 946 1650 194 818
Metastatic lymph node x x 35300 810 3600 609 579
Uninvolved lymph node 0.3
a 0
a 24 600 274 2.5 0
740 0.7
0
Serum n.d 0.9 n.d. n.d. 5.6 1.8 2
Concentrations of SCCA in the cells and post-surgical samples are presented in nanogram per milligram of cell protein and in the sera in
nanogram per millilitre of serum
x no metastatic nodes found, n.d. not determined
aMore than one lymph node of this patient was tested
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Fig. 4 SCCA1 and SCCA2 expression (green) in stimulated PBMC
and UT-SCC-8 and HeLa cell lines. Confocal microscope images. a
Chromomycin-stained nuclei (red), b SCCA 1 or SCCA 2 fluores-
cence, c transmitted light images, d an overlay of panels b on a,
illustrating the cytoplasmic fluorescence
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upon PBMC stimulation. Similarly, squamous epithelium-
derived cells, such as normal keratinocytes, normal non-
keratinocyte cells, cervical squamous cell carcinoma and
adenocarcinoma cells, have been shown to express higher
m R N Al e v e l so fS C C A 1t h a no fS C C A 2[ 20]. However,
in squamous cell carcinomas of head and neck, Stenman et
al. [15] observed a decrease in SCCA1/SCCA2 expression
ratio in malignant squamous cells; that is, the SCCA1/
SCCA2 mRNA ratios were lower in tumour tissue
(median ratio<5) than in normal epithelium (median
ratio>10). Those ratios were also lower in primary
tumours that developed into recurrent disease and in
recurrent secondary tumours than in non-recurring primary
tumours. Similarly, Hsu et al. [16] found that in the uterine,
the SCCA1/SCCA2 mRNA ratios were progressively
decreased in normal vs. dysplastic and dysplastic vs. cancer
cells. In addition, the decreased SCCA1/SCCA2 ratio carried
a higher risk for recurrence in early-stage uterine cervical
cancer.
The published data on SCCA expression in normal
human tissues are inconsistent. In the squamous cells of
normal epithelia, some authors reported the SCCA immu-
noreactivity [21, 22], while others [23, 24] detected low or
absent SCCA expression. The discrepancies might result
from the different antibody specificities and tissue origins.
Cataltepe et al. [12] have shown stronger SCCA1 and
SCCA2 immunoreactivity in normal skin over areas of
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Fig. 5 Expression of total
SCCA and its forms (SCCA1
and SCCA2) in the parafin
sections of VSCC and metastatic
lymph node sections.
Immunohistochemical staining
(Santa Cruz MAb)
Donor III
Normal PBMC SCCA1 mRNA Anti-SCCA1 SCCA2 mRNA Anti-SCCA2
0 −− −− −
1d + − + −−
1d/PHA −− −++ / −
2d/PHA − +/−− − +
3d/PHA −− −− −
4d/PHA − + −− −
5d/PHA − +/−− − +
6d/PHA −− −− −
Table 3 A comparison
of SCCA1 and SCCA2 expres-
sion in the peripheral blood
mononuclear cells (PBMC)
mRNA expression was evaluated
by nested RT-PCR, protein
expression was estimated by
immunocytochemistry
(+) present, (−) absent,
(+/−) trace expression
564 Tumor Biol. (2010) 31:559–567inflammation. This observation indicates that the expres-
sion of SCCA in the skin can be induced by local
inflammation. Indeed, SCCA has been recognised as a
marker of inflammatory skin diseases [23, 25, 26].
Interestingly, in the squamous cell carcinomas of the
tongue, Yasumatsu et al. [27] observed SCCA1 immunos-
taining in the T-lymphocytes peripheral to cancer cells and
found this staining, but not SCCA1 expression in cancer
cells, to significantly correlate with elevated serum SCCA
concentrations. We showed here SCCA immunoreactivity
in vulvar tumour-associated granulocytes. Thus, the source
of serum SCCA may not necessarily be cancer cells but
other tumour-associated cells, such as infiltrating immune
cells. Elevated serum SCCA associated with several non-
neoplastic dermatological diseases [23, 25] as well as with
renal failure or lung diseases [28] support the possible role
of different non-neoplastic cells in SCCA release. Further-
more, Van der Sijde et al. [29], who found serum SCCA
assessment a useful tool for the early detection of recurrent
VSCC, also observed 25% of false-positive (i.e. in patients
with no cancer) SCCA results in patients with benign skin
disorders. In addition, elevated concentrations of serum
SCCA and/or C-reactive protein were reported to be
independent unfavourable prognostic factors in head and
neck squamous cell carcinomas [30], which links SCCAwith
systemic symptoms of cancer-related inflammation. Taken
together, these data suggest that SCCA is not only a marker
of squamous cell carcinomas but also of inflammatory
conditions, and although high sensitivity of serum SCCA
determination in cancer patients is generally appreciated, at
the same time its limited specificity is evident.
Here, we also examined SCCA expression in VSCC
patients. The levels of SCCA protein and mRNA induced
in normal PBMC were several orders of magnitude lower
than those found in the vulvar tumour cells and in the cells
of tumour-adjacent tissues and lymph nodes. However, high
levels of SCCA in the local tumour microenvironment and
regional metastatic sites in patients with VSCC seem not
to imply elevated serum SCCA levels, as few of those
patients had serum SCCA concentrations above the
normal level. In patients with early stage VSCC, consis-
tently with our data, other researchers have shown mean
serum SCCA level to be below the cut-off value [4].
Serum SCCA levels were found not to be associated with
lymph node involvement [4, 29, 31]. In advanced VSCC
(FIGO stage IV), less than 40% of patients present
elevated serum SCCA concentrations [4, 29].
The origin of serum SCCA in patients with SCC remains
an open question. Uemura et al. [13]h a v es h o w nt h e
lack of SCCA secretion by the SCC cells, but other
studies contradicted this result [32, 33]. Our analysis of
SCCA concentrations in the spent media of stimulated
PBMC, and of the squamous epithelia-derived cells of the
HaCat and SKG-IIIa cervical cancer cell lines, showed
SCCA in the culture media of SKG-IIIa cells but not of
PBMC or HaCat cells. Thus, SCCA identified in body fluids
may either be secreted by the cells and/or may derive from
dying cells. In addition, SCCA expression and secretion is
inducible by the Th2 cytokines, IL-13 and IL-4 in normal
squamous epithelial cells [26, 33–35]. The Th1 to Th2 shift
is regarded as typical of cancer; still, only SCC patients
present elevated serum SCCA concentrations. Therefore, we
hypothesise that an increase in the serum SCCA levels in
patients with squamous cell carcinomas may be associated
with SCCA induction by cytokines in normal squamous
epithelial cells present in SCC microenvironment.
In summary, normal, activated PBMCs express SCCA1
and SCCA2 at both the mRNA and protein level, but the
two forms of SCCA are not necessarily expressed concur-
rently. We could not demonstrate that cancer-related
inflammatory cells are potentially a significant source of
circulating SCCA in VSCC. In vulvar SCC patients, not
only tumours but also metastatic lymph nodes are potential
sources of SCCA protein. We think that the raised levels of
serum SCCA observed by some researchers in the advanced
stages of vulvar carcinoma [36] may result from secondary
changes related to the disease progression, such as alter-
ations induced by metastatic cancer cells in their microen-
vironment and/or an increase in proinflammatory cytokines.
These changes create a feedback between local and
systemic inflammation, a phenomenon that we have
discussed elsewhere [37]. The exact mechanisms of
releasing of SCCA into the body fluids remain to be
resolved.
Cell types
Cancers Granulocyte Lymphocytes Plasmocytes Normal basal epithelial
TNT N T N T N T N
Total SCCA + + −−− − −−− 0
SCCA1 −−+0−−− 0 − 0
SCCA2 + + + 0 −−− 0+ 0
Table 4 Total SCCA, SCCA1
and SCCA2 expression accord-
ing to cell types, identified by
immunohistochemical examina-
tion of vulvar tumour and in-
guinal lymph node sections
T tumour, N inguinal lymph
node, 0 no such cells identified,
(+) present, (−) absent
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